MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Oseltamivir phosphate

CAS No. : 204255-11-8

MCE 站：Oseltamivir phosphate

产品活性：Oseltamivir phosphate (GS 4104) 是一种神经氨酸酶 (neuraminidase) 抑制剂，用于流感 (influenza A 和 B) 的研究。

研究领域：Anti-infection

作用靶点：Influenza Virus

In Vitro: Oseltamivir phosphate (OP) is a prodrug that is readily absorbed from the gastrointestinal tract after oral administration and is extensively converted predominantly by hepatic esterases to Oseltamivir carboxylate (OC). Oseltamivir phosphate is a widely used anti-influenza sialidase inhibitor. The metabolic activity of CMA07 and CMT-U27 cell lines is significantly decreased with 305 μM Oseltamivir phosphate treatment (p=0.005 and p<0.0001 respectively) using One Way ANOVA testes. In contrast, no statistically significant alterations are observed with 0.305 μM (p=0.9781), 3.05 μM (p=0.7436) and 30.5 μM (p=0.9623) of Oseltamivir phosphate treatments when compare with control cells. Finally, to assess the effect of Oseltamivir phosphate on CMA07 and CMT-U27 programmed cell death, and given that 305 μM Oseltamivir phosphate treatment impaired cell metabolic activity, a programmed cell death measurement is performed with the TUNEL assay. Twenty-four hour Oseltamivir phosphate treatment, specifically at 305 μM, significantly increases CMA07 (p=0.001) and CMT-U27 (p=0.0002) DNA fragmentation, suggesting promotion of programmed cell death, when compare with lower Oseltamivir concentrations, or with PBS.

In Vivo: Oseltamivir phosphate-treated mice present significantly more inflammatory infiltrate in primary tumors (p=0.01). Ki-67 antigen and caspase-3 protein are used to assess CMT-U27 xenograft tumor cell proliferation and apoptosis respectively. Virtually no differences are found in Ki-67 and caspase 3 (p=0.2) expression between Oseltamivir-treated and non-treated mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Acetylcysteine  |  U0126-EtOH  |  Tunicamycin  |  Vadimezan  |  Favipiravir  |  Curcumin  |  Camptothecin  |  Aprotinin  |  Oseltamivir acid  |  Geldanamycin  |  Emricasan  |  Rifampicin  |  Baicalein  |  Mycophenolic acid  |  AG-1478  |  AEBSF hydrochloride  |  α-Vitamin E  |  Nitazoxanide  |  GSK 650394  |  Umifenovir hydrochloride  |  Spermine  |  Isoliquiritigenin  |  Oxymatrine  |  6-Diazo-5-oxo-L-nor-Leucine  |  Pimodivir  |  Pentagalloylglucose  |  Naringenin  |  Catechin  |  Chlorogenic acid  |  Zanamivir

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。